IMC Chicago
NBIX icon

IMC Chicago’s Neurocrine Biosciences NBIX Stock Holding History

IMC Chicago’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.98M Buy
15,000
+4,900
+49% +$650K ﹤0.01% 2581
2025
Q4 		$1.43M Buy
+10,100
New +$1.46M ﹤0.01% 2695

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IMC Chicago's NBIX Position: Q1 2026 in Review

IMC Chicago opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 4,951 shares worth $652K. The stake represents ﹤0.01% of the portfolio and ranks #3747 among its holdings.

694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • IMC Chicago held 4,951 shares of Neurocrine Biosciences worth $652K as of Q1 2026.
  • Neurocrine Biosciences was a new IMC Chicago position in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #3747 holding.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.